|

Surufatinib Clinical Trials

8 actively recruiting trials

▲ +1 trial since June 2026

Also known as: HMPL-012, SULANDA

Pipeline

Phase 2: 7Phase 4: 1

Top Sponsors

  • Sun Yat-sen University3
  • Shanghai Zhongshan Hospital1
  • Shanghai Chest Hospital1
  • Peking University1
  • Fudan University1

Indications

  • Cancer8
  • Lung Cancer3
  • Consolidation Therapy1
  • Adenocarcinoma of Small Intestine1
  • Pulmonary Neuroendocrine Tumor1

Other8 trials

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer
Phase 2
Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
Phase 2
Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
Phase 2
Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms
Phase 4
Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)
Phase 2
Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors
Phase 2
Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma
Phase 2
Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.